Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Common Equity (2016 - 2025)

CV Sciences' Common Equity history spans 14 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Common Equity fell 29.76% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, down 29.76%, while the annual FY2024 figure was $1.8 million, 38.17% down from the prior year.
  • Common Equity for Q3 2025 was $1.5 million at CV Sciences, down from $1.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $12.0 million in Q1 2021 and bottomed at -$777000.0 in Q4 2022.
  • The 5-year median for Common Equity is $2.5 million (2024), against an average of $3.8 million.
  • The largest annual shift saw Common Equity crashed 121.93% in 2022 before it skyrocketed 473.62% in 2023.
  • A 5-year view of Common Equity shows it stood at $3.5 million in 2021, then plummeted by 121.93% to -$777000.0 in 2022, then surged by 473.62% to $2.9 million in 2023, then tumbled by 38.17% to $1.8 million in 2024, then dropped by 14.26% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CVSI's Common Equity are $1.5 million (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q1 2025).